Adverse reactions with calcium antagonists.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001552:Benzazepines / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002301:Cardiac Glycosides / Q000627:therapeutic use; D003864:Depression, Chemical; D004110:Diltiazem / Q000009:adverse effects*; D004347:Drug Interactions; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D009200:Myocardial Contraction / Q000187:drug effects; D009543:Nifedipine / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D014700:Verapamil / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001552:Benzazepines; D002121:Calcium Channel Blockers; D002301:Cardiac Glycosides; D007328:Insulin; D011725:Pyridines; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine